{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:05:26Z","timestamp":1792130726782,"version":"4.4.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["202201011420"],"award-info":[{"award-number":["202201011420"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274214"],"award-info":[{"award-number":["82274214"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Biochemistry and Biophysics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.abb.2024.110024","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T22:59:07Z","timestamp":1714690747000},"page":"110024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Role of FXR in the development of NAFLD and intervention strategies of small molecules"],"prefix":"10.1016","volume":"757","author":[{"given":"Jiachan","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuerong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingxing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1016\/j.abb.2024.110024_bib1","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","article-title":"MAFLD: how is it different from NAFLD?","volume":"29","author":"Gofton","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"issue":"10","key":"10.1016\/j.abb.2024.110024_bib2","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.abb.2024.110024_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154703","article-title":"Targeting mTOR\/YY1 signaling pathway by quercetin through CYP7A1-mediated cholesterol-to-bile acids conversion alleviated type 2 diabetes mellitus induced hepatic lipid accumulation","volume":"113","author":"Yang","year":"2023","journal-title":"Phytomedicine : international journal of phytotherapy and phytopharmacology"},{"issue":"2","key":"10.1016\/j.abb.2024.110024_bib4","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology (Baltimore, Md"},{"issue":"3","key":"10.1016\/j.abb.2024.110024_bib5","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology (Baltimore, Md"},{"issue":"4","key":"10.1016\/j.abb.2024.110024_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.abb.2024.110024_bib7","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.metabol.2016.02.014","article-title":"Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease","volume":"65","author":"Mota","year":"2016","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.abb.2024.110024_bib8","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1194\/jlr.R066357","article-title":"Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis","volume":"57","author":"Hirsova","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.abb.2024.110024_bib9","first-page":"283","article-title":"Nonalcoholic fatty liver disease","volume":"8","author":"Schaffner","year":"1986","journal-title":"Prog. Liver Dis."},{"issue":"1","key":"10.1016\/j.abb.2024.110024_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology (Baltimore, Md"},{"issue":"3","key":"10.1016\/j.abb.2024.110024_bib11","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol. : the official clinical practice journal of the American Gastroenterological Association"},{"issue":"12","key":"10.1016\/j.abb.2024.110024_bib12","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.abb.2024.110024_bib13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.cmet.2023.06.012","article-title":"Nonalcoholic fatty liver disease mortality may not be decreasing: a need for careful interpretation of GBD 2019 estimates of liver deaths","volume":"35","author":"Paik","year":"2023","journal-title":"Cell Metabol."},{"key":"10.1016\/j.abb.2024.110024_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113869","article-title":"Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis","volume":"176","author":"Kumar","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.abb.2024.110024_bib15","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.abb.2024.110024_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111678","article-title":"Recent advances on FXR-targeting therapeutics","volume":"552","author":"Panzitt","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"issue":"7","key":"10.1016\/j.abb.2024.110024_bib17","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","article-title":"Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease","volume":"152","author":"Ch\u00e1vez-Talavera","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.abb.2024.110024_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jhep.2021.03.020","article-title":"FXR agonists for NASH: how are they different and what difference do they make?","volume":"75","author":"Kremoser","year":"2021","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.abb.2024.110024_bib19","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/s41401-021-00849-4","article-title":"FXR: structures, biology, and drug development for NASH and fibrosis diseases","volume":"43","author":"Tian","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"11","key":"10.1016\/j.abb.2024.110024_bib20","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/cr.2008.289","article-title":"FXR: a metabolic regulator and cell protector","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.abb.2024.110024_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111650","article-title":"Immunomodulatory functions of FXR","volume":"551","author":"Fiorucci","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"issue":"1","key":"10.1016\/j.abb.2024.110024_bib22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1074\/jbc.M209505200","article-title":"Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation","volume":"278","author":"Zhang","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.abb.2024.110024_bib23","doi-asserted-by":"crossref","first-page":"R1400","DOI":"10.1152\/ajpregu.00781.2006","article-title":"The farnesoid X receptor FXRalpha\/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution","volume":"293","author":"Cai","year":"2007","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.abb.2024.110024_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2021.108893","article-title":"Identification and characterization of novel splice variants of human farnesoid X receptor","volume":"705","author":"Mustonen","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.abb.2024.110024_bib25","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.csbj.2021.04.029","article-title":"Farnesoid X receptor (FXR): structures and ligands","volume":"19","author":"Jiang","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"32","key":"10.1016\/j.abb.2024.110024_bib26","doi-asserted-by":"crossref","first-page":"12535","DOI":"10.1074\/jbc.RA118.004188","article-title":"Structural insights into the heterodimeric complex of the nuclear receptors FXR and RXR","volume":"293","author":"Zheng","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.abb.2024.110024_bib27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00281-022-00935-7","article-title":"Bile acids and their receptors: modulators and therapeutic targets in liver inflammation","volume":"44","author":"Bertolini","year":"2022","journal-title":"Semin. Immunopathol."},{"issue":"2","key":"10.1016\/j.abb.2024.110024_bib28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.abb.2024.110024_bib29","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1053\/j.gastro.2020.07.036","article-title":"FXR isoforms control different metabolic functions in liver cells via binding to specific DNA motifs","volume":"159","author":"Ramos Pittol","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.abb.2024.110024_bib30","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41467-019-14138-6","article-title":"SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.abb.2024.110024_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101238","article-title":"Metabolic-associated fatty liver disease and lipoprotein metabolism","volume":"50","author":"Heeren","year":"2021","journal-title":"Mol. Metabol."},{"issue":"10","key":"10.1016\/j.abb.2024.110024_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102772","article-title":"Involvement of autophagy in ageing and chronic cholestatic diseases","volume":"10","author":"Pinto","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.abb.2024.110024_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153629","article-title":"Yangonin modulates lipid homeostasis, ameliorates cholestasis and cellular senescence in alcoholic liver disease via activating nuclear receptor FXR","volume":"90","author":"Kong","year":"2021","journal-title":"Phytomedicine : international journal of phytotherapy and phytopharmacology"},{"key":"10.1016\/j.abb.2024.110024_bib34","doi-asserted-by":"crossref","first-page":"e005","DOI":"10.1621\/nrs.08005","article-title":"Deciphering the nuclear bile acid receptor FXR paradigm","volume":"8","author":"Modica","year":"2010","journal-title":"Nucl. Recept. Signal."},{"issue":"8","key":"10.1016\/j.abb.2024.110024_bib35","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metabol."},{"issue":"1","key":"10.1016\/j.abb.2024.110024_bib36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1055\/s-0036-1571296","article-title":"Nuclear receptor modulation for the treatment of nonalcoholic fatty liver disease","volume":"36","author":"Fuchs","year":"2016","journal-title":"Semin. Liver Dis."},{"issue":"10","key":"10.1016\/j.abb.2024.110024_bib37","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1136\/gutjnl-2016-312975","article-title":"Fibroblast growth factor 15\/19 (FGF15\/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration","volume":"66","author":"Alvarez-Sola","year":"2017","journal-title":"Gut"},{"issue":"22","key":"10.1016\/j.abb.2024.110024_bib38","doi-asserted-by":"crossref","first-page":"8732","DOI":"10.1074\/jbc.RA119.008360","article-title":"Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis","volume":"294","author":"Byun","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.abb.2024.110024_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155200","article-title":"Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK\/mTOR signaling pathway","volume":"131","author":"Yan","year":"2022","journal-title":"Metab., Clin. Exp."},{"issue":"5","key":"10.1016\/j.abb.2024.110024_bib40","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jcmgh.2022.07.012","article-title":"Hepatocyte-secreted autotaxin exacerbates nonalcoholic fatty liver disease through autocrine inhibition of the PPAR\u03b1\/FGF21 Axis","volume":"14","author":"Qiu","year":"2022","journal-title":"Cellular and molecular gastroenterology and hepatology"},{"issue":"4","key":"10.1016\/j.abb.2024.110024_bib41","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","article-title":"Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut"},{"issue":"7932","key":"10.1016\/j.abb.2024.110024_bib42","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41586-022-05299-4","article-title":"Gut bacteria alleviate smoking-related NASH by degrading gut nicotine","volume":"610","author":"Chen","year":"2022","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.abb.2024.110024_bib43","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00535-024-02082-2","article-title":"Indoleamine 2,3-dioxygenase 1-mediated iron metabolism in macrophages contributes to lipid deposition in nonalcoholic steatohepatitis","volume":"59","author":"Wu","year":"2024","journal-title":"J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.abb.2024.110024_bib44","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.abb.2024.110024_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodchem.2023.135947","article-title":"The structure of triglycerides impacts the digestibility and bioaccessibility of nutritional lipids during in vitro simulated digestion","volume":"418","author":"Wang","year":"2023","journal-title":"Food Chem."},{"issue":"6024","key":"10.1016\/j.abb.2024.110024_bib47","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1198363","article-title":"FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis","volume":"331","author":"Kir","year":"2011","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.abb.2024.110024_bib48","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/ijo.2012.181","article-title":"Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects","volume":"37","author":"Rametta","year":"2013","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.abb.2024.110024_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117997","article-title":"IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease","volume":"256","author":"Xiao","year":"2020","journal-title":"Life Sci."},{"issue":"45","key":"10.1016\/j.abb.2024.110024_bib50","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.3748\/wjg.v25.i45.6607","article-title":"LB100 ameliorates nonalcoholic fatty liver disease via the AMPK\/Sirt1 pathway","volume":"25","author":"Chen","year":"2019","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.abb.2024.110024_bib51","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.diabet.2014.01.005","article-title":"Molecular mechanisms of GLUT4 regulation in adipocytes","volume":"40","author":"Govers","year":"2014","journal-title":"Diabetes Metabol."},{"key":"10.1016\/j.abb.2024.110024_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154771","article-title":"Mebhydrolin ameliorates glucose homeostasis in type 2 diabetic mice by functioning as a selective FXR antagonist","volume":"119","author":"Zhao","year":"2021","journal-title":"Metab., Clin. Exp."},{"key":"10.1016\/j.abb.2024.110024_bib53","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.phymed.2018.09.006","article-title":"Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor","volume":"53","author":"Dong","year":"2019","journal-title":"Phytomedicine : international journal of phytotherapy and phytopharmacology"},{"issue":"5","key":"10.1016\/j.abb.2024.110024_bib54","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.3892\/mmr.2016.5081","article-title":"3-Deoxyglucosone induces insulin resistance by impairing insulin signaling in HepG2 cells","volume":"13","author":"Liang","year":"2016","journal-title":"Mol. Med. Rep."},{"issue":"8","key":"10.1016\/j.abb.2024.110024_bib55","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.chembiol.2023.06.012","article-title":"Insulin sensitization by small molecules enhancing GLUT4 translocation","volume":"30","author":"Yin","year":"2023","journal-title":"Cell Chem. Biol."},{"issue":"6","key":"10.1016\/j.abb.2024.110024_bib56","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.apsb.2021.03.038","article-title":"Notoginsenoside Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and insulin resistance in mice","volume":"11","author":"Ding","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.abb.2024.110024_bib57","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/hep.29857","article-title":"Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism","volume":"68","author":"Pathak","year":"2018","journal-title":"Hepatology (Baltimore, Md"},{"issue":"12","key":"10.1016\/j.abb.2024.110024_bib58","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin","volume":"24","author":"Sun","year":"2018","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.abb.2024.110024_bib59","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5223\/pghn.2013.16.1.22","article-title":"Gut microbiota and clinical disease: obesity and nonalcoholic Fatty liver disease","volume":"16","author":"Park","year":"2013","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"issue":"47","key":"10.1016\/j.abb.2024.110024_bib60","doi-asserted-by":"crossref","first-page":"14176","DOI":"10.1021\/acs.jafc.1c05596","article-title":"Novel sesquiterpene glycoside from loquat leaf alleviates type 2 diabetes mellitus combined with nonalcoholic fatty liver disease by improving insulin resistance, oxidative stress, inflammation, and gut microbiota composition","volume":"69","author":"Chen","year":"2021","journal-title":"J. Agric. Food Chem."},{"issue":"1S Suppl 1","key":"10.1016\/j.abb.2024.110024_bib61","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1097\/MEG.0000000000002140","article-title":"Gut microbiota in nonalcoholic fatty liver diseases with and without type-2 diabetes mellitus","volume":"33","author":"Ebrahimzadeh Leylabadlo","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"7285","key":"10.1016\/j.abb.2024.110024_bib62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature08821","article-title":"A human gut microbial gene catalogue established by metagenomic sequencing","volume":"464","author":"Qin","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.abb.2024.110024_bib63","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1017\/S0007114510000176","article-title":"Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women","volume":"104","author":"Santacruz","year":"2010","journal-title":"Br. J. Nutr."},{"issue":"1","key":"10.1016\/j.abb.2024.110024_bib64","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/MOG.0000000000000139","article-title":"The gut microbiome in health and in disease","volume":"31","author":"Shreiner","year":"2015","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"3","key":"10.1016\/j.abb.2024.110024_bib65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00535-018-1521-8","article-title":"Antimicrobial proteins: intestinal guards to protect against liver disease","volume":"54","author":"Hendrikx","year":"2019","journal-title":"J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.abb.2024.110024_bib66","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00535-019-01649-8","article-title":"Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives","volume":"55","author":"Hu","year":"2020","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.abb.2024.110024_bib67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.freeradbiomed.2022.08.037","article-title":"Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate experimental non-alcoholic steatohepatitis via Nrf2\/NQO-1 pathway","volume":"192","author":"Kang","year":"2022","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.abb.2024.110024_bib68","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.3389\/fmicb.2017.02010","article-title":"Prebiotic and synbiotic modifications of beta oxidation and lipogenic gene expression after experimental hypercholesterolemia in rat liver","volume":"8","author":"Alves","year":"2017","journal-title":"Front. Microbiol."},{"issue":"4","key":"10.1016\/j.abb.2024.110024_bib69","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.BAD-0008-2017","article-title":"Fecal microbiota transplantation: therapeutic potential for a multitude of diseases beyond Clostridium difficile","volume":"5","author":"Bakker","year":"2017","journal-title":"Microbiol. Spectr."},{"issue":"3","key":"10.1016\/j.abb.2024.110024_bib70","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/19490976.2017.1293224","article-title":"Fecal microbiota transplantation in metabolic syndrome: history, present and future","volume":"8","author":"de Groot","year":"2017","journal-title":"Gut Microb."},{"issue":"2","key":"10.1016\/j.abb.2024.110024_bib71","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/apt.14397","article-title":"Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease","volume":"47","author":"Woodhouse","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.abb.2024.110024_bib72","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1136\/gutjnl-2012-303816","article-title":"Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice","volume":"62","author":"Le Roy","year":"2013","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.abb.2024.110024_bib73","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41598-017-01751-y","article-title":"Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.abb.2024.110024_bib74","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1053\/j.gastro.2012.06.031","article-title":"Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome","volume":"143","author":"Vrieze","year":"2012","journal-title":"Gastroenterology"},{"issue":"10290","key":"10.1016\/j.abb.2024.110024_bib75","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.abb.2024.110024_bib76","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism","volume":"24","author":"Wahlstr\u00f6m","year":"2016","journal-title":"Cell Metabol."},{"issue":"5","key":"10.1016\/j.abb.2024.110024_bib77","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1053\/j.gastro.2011.07.046","article-title":"Bile acid is a host factor that regulates the composition of the cecal microbiota in rats","volume":"141","author":"Islam","year":"2011","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.abb.2024.110024_bib78","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.abb.2024.110024_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101603","article-title":"Obesity-induced miR-802 directly targets AMPK and promotes nonalcoholic steatohepatitis in mice","volume":"66","author":"Sun","year":"2022","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.abb.2024.110024_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154797","article-title":"A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage","volume":"120","author":"Huang","year":"2021","journal-title":"Metab., Clin. Exp."},{"issue":"7","key":"10.1016\/j.abb.2024.110024_bib81","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1111\/liv.14490","article-title":"A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction","volume":"40","author":"An","year":"2020","journal-title":"Liver Int. : official journal of the International Association for the Study of the Liver"},{"issue":"11","key":"10.1016\/j.abb.2024.110024_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2022.100544","article-title":"Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis","volume":"4","author":"Schramm","year":"2022","journal-title":"JHEP reports : innovation in hepatology"},{"issue":"11","key":"10.1016\/j.abb.2024.110024_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2023.100874","article-title":"Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2(-\/-) mouse model of sclerosing cholangitis","volume":"5","author":"Fuchs","year":"2023","journal-title":"JHEP reports : innovation in hepatology"},{"issue":"27","key":"10.1016\/j.abb.2024.110024_bib84","doi-asserted-by":"crossref","first-page":"10338","DOI":"10.1021\/acs.jafc.3c01067","article-title":"Curcumin alleviates high-fat diet-induced nonalcoholic steatohepatitis via improving hepatic endothelial function with microbial biotransformation in rats","volume":"71","author":"Wu","year":"2023","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.abb.2024.110024_bib85","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jare.2021.06.001","article-title":"Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism","volume":"34","author":"Wang","year":"2021","journal-title":"J. Adv. Res."},{"issue":"1","key":"10.1016\/j.abb.2024.110024_bib86","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41401-022-00921-7","article-title":"Caffeic acid phenethyl ester suppresses intestinal FXR signaling and ameliorates nonalcoholic fatty liver disease by inhibiting bacterial bile salt hydrolase activity","volume":"44","author":"Zhong","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.abb.2024.110024_bib87","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41522-023-00399-z","article-title":"Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism","volume":"9","author":"Liu","year":"2023","journal-title":"NPJ biofilms and microbiomes"},{"issue":"3","key":"10.1016\/j.abb.2024.110024_bib88","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/MOL.0000000000000303","article-title":"Bile salts in control of lipid metabolism","volume":"27","author":"Schonewille","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"issue":"10215","key":"10.1016\/j.abb.2024.110024_bib89","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.abb.2024.110024_bib90","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR agonists for MASH therapy: lessons and perspectives from obeticholic acid","volume":"44","author":"Wang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.abb.2024.110024_bib91","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.biopha.2018.05.135","article-title":"Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice","volume":"105","author":"Yan","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"10.1016\/j.abb.2024.110024_bib92","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/ptr.6743","article-title":"Extract of Schisandra chinensis fruit protects against metabolic dysfunction in high-fat diet induced obese mice via FXR activation","volume":"34","author":"Gu","year":"2020","journal-title":"Phytother Res."}],"container-title":["Archives of Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003986124001437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003986124001437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:08:08Z","timestamp":1778630888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003986124001437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":91,"alternative-id":["S0003986124001437"],"URL":"https:\/\/doi.org\/10.1016\/j.abb.2024.110024","relation":{},"ISSN":["0003-9861"],"issn-type":[{"value":"0003-9861","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of FXR in the development of NAFLD and intervention strategies of small molecules","name":"articletitle","label":"Article Title"},{"value":"Archives of Biochemistry and Biophysics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abb.2024.110024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110024"}}